Skip to content
Pictured: JOURNAVX bottle and tablet (Photo: Business Wire) The Jan. 30 approval of Vertex Pharmaceuticals’ JOURNAVX™ (suzetrigine), for acute pain, represents a watershed in […]
FDA approves Vertex’s pain treatment: A victory in the war against the opioid epidemic Read More »
Reforms to prevent middlemen from driving up drug prices and legislation encouraging the development of oral medications and rare disease treatments were called top
What BIO’s watching in the new Congress Read More »
Legislation introduced last year to ease widespread commercialization of sustainable aviation fuel (SAF) was reintroduced Jan. 16 as one of the early measures proposed
Farm to Fly Act reintroduced in Senate would give SAF wings Read More »
The world needs regulatory reform and greater R&D investment to enable “moonshot” biotech innovations in food production that can meet our growing food needs,
Nobel and World Food Prize holders: Enable biotech innovation for food Read More »
The year in biotech M&A activity got off to a promising start at JPM Week with announcements of some multi-billion-dollar deals. The flurry of
Multi-billion-dollar deals at JPM Week augur a busy BIO CEO 2025 Read More »
January brought important changes for the roughly 53 million seniors enrolled in Medicare prescription drug plans. Some of these changes are automatic, while others
Medicare Part D plans are changing for 2025 – here’s what patients need to know Read More »
Pharmacy benefit managers (PBMs) make billions in profit while driving up the price of prescription drugs with markups that can exceed 1,000%, according to
FTC’s second report on PBMs blasts drug price markups of 1,000% Read More »
As science progresses, we need parallel progress in making breakthrough treatments widely available, BIO President & CEO John F. Crowley said at a Jan.
BIO CEO urges innovation in access at White House CGT forum Read More »
The increased interest in JPM Week this year is an indication of an improved dealmaking environment for biotech, according to experts for the Biotechnology
Buzz around JPM Week partnering bodes well for biotech dealmaking, BIO says Read More »
A dispute panel ruled that Mexico’s planned ban on imports of biotech corn is “not based on relevant scientific principles” and would violate the U.S.-Mexico-Canada
USMCA dispute panel halts Mexico’s ban on biotech corn Read More »
